Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Trametinib in the treatment of melanoma.

Expert opinion on biological therapy - 1 May 2015

Thota Ramya, Johnson Douglas B, Sosman Jeffrey A

Abstract excerpt

INTRODUCTION: Aberrant MAPK pathway signaling is a hallmark of melanoma. Mitogen/extracellular signal-regulated kinase (MEK) 1/2 are integral components of MAPK signaling. Several MEK inhibitors have demonstrated activity as single agents and in combination with other therapies. Trametinib was the first MEK inhibitor approved for use in treatment of advanced BRAF(V600) mutant melanoma as a single agent and in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Protein Kinase Inhibitors
Share to Pyridones
Share to Pyrimidinones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Clinical Trials as Topic

Share to Drug Evaluation, Preclinical

Share to Immunotherapy

Share to Melanoma

Source

Open in PubMed Open full text

Identifiers

PMID: 25812921
DOI: 10.1517/14712598.2015.1026323
PMCID: PMC6684215

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Trametinib in the treatment of melanoma.PMID 25812921Read ↗

Trametinib (GSK1120212) in the treatment of melanomaSemantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

The role of MEK inhibitors in the treatment of metastatic melanoma.Semantic proximity Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Semantic proximity Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

BRAF and MEK gene rearrangements in melanoma: implications for targeted therapy.Semantic proximity Read ↗

Vemurafenib/dabrafenib and trametinibSemantic proximity Read ↗

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.Semantic proximity Read ↗

Targeted Therapy for Melanoma.Semantic proximity Read ↗

Dabrafenib for the treatment of melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.